Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments

Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Inclusion Criteria:

• Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
• Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
• Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration

Exclusion Criteria:

• Patients being hospitalized
• Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
• Patients who have more than 400mg/dl triglyceride(TG) at the registration time